遺傳性血管水腫(HAE)治療的全球市場:各級藥品，不同治療，各給藥途徑，各流通管道，各用途，各地區 - 預測分析(2022年～2028年)

全球遺傳性血管水腫(HAE)治療的市場規模預測將從2021年的25億美元到2028年達到45億美元，在預測期間(2022年～2028年)預計將以年複合成長率8.7％的速度成長。市場重大的促進因素是全球遺傳性血管水腫(HAE)患者的增加。

本報告提供全球遺傳性血管水腫(HAE)治療市場相關調查分析，提供市場動態及預測，市場區隔分析，企業簡介等資訊。

目錄

摘要整理

市場概要

母市場分析

市場概要

市場規模

• 市場動態
• 促進因素
• 機會
• 阻礙因素
• 課題
• SWOT分析

主要市場的考察

• 技術分析
• 價格分析
• 供應鏈分析
• 價值鏈分析
• 市場生態系統
• IP分析
• 貿易分析
• Start-Ups分析
• 原料的分析
• 革新矩陣
• 開發中產品分析
• 宏觀經濟指標

COVID的影響

• 簡介
• 經濟情勢的影響的評估
• 修正的市場規模
• COVID對主要市場區隔的影響
• COVID策略:各企業

市場動態及預測

• 市場動態
• 促進因素
• 機會
• 阻礙因素
• 課題
• 法規形勢
• SWOT分析
• 波特的五力分析
• 未來中斷的特別見解

全球遺傳性血管水腫(HAE)治療市場:各級藥品

• 市場區隔
• C1 - 酯?抑製劑
• 白蘭地激? B2 受體拮抗劑
• 激?釋放?抑製劑
• 其他

全球遺傳性血管水腫(HAE)治療市場:不同治療

• 市場區隔
• 預防
• 隨選

全球遺傳性血管水腫(HAE)治療市場:各給藥途徑

• 市場區隔
• 靜脈
• 皮下
• 口服

全球遺傳性血管水腫(HAE)治療市場:各流通管道

• 市場區隔
• 醫院藥局
• 零售藥局

市場規模:各地區

• 北美
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 其他的歐洲
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他的亞太地區
• 南美
  • 巴西
  • 其他的南美
• 中東·非洲
  • GCC各國
  • 南非
  • 其他的中東·非洲

主要企業簡介

• 競爭情形
• Takeda Pharmaceutical Company Limited (Japan)
• CSL Limited (Australia)
• Biocryst Pharmaceuticals (U.S.)
• Pharming Group N.V. (Netherlands)
• Ionis Pharmaceuticals (U.S.)
• Novartis AG (Switzerland)
• Centogene AG (Germany)
• Sanofi (France)
• KalVista Pharmaceuticals (U.S.)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc. (U.K.)
• AstraZeneca (U.K)
• Medtronic (Ireland)
• Eli Lilly (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Amgen Inc. (U.S.)
• Johnson & Johnson Services (U.S.)
• AbbVie Inc. (U.S.)
• Incyte Corporation (U.S.)
• Bayer AG (Germany)

Global Hereditary Angioedema Treatment Market was valued at USD 2.5 billion in 2021 and it is expected to reach at USD 4.5 billion by 2028, at a CAGR of 8.7% over the forecast period (2022-2028).

A significant market driver is the increase of hereditary angioedema (HAE) patients worldwide.

According to the National Organization for Rare Disorders (NORD), the ailment affects 1 to 9 persons out of every 100,000 people. Due to underreporting and misdiagnosis, the real number of people with the ailment is much higher.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hereditary Angioedema Treatment Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined by using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Segments covered in this report:

Global hereditary angioedema treatment market is segmented based on drug class, treatment type, route of administration, distribution channel, application, and region. Based on drug class, the market is segmented into C1-esterase inhibitor, Brandykinin B2 receptor antagonist, Kallikrein inhibitor, others. Based on treatment, the market is divided into prophylaxis, on demand. Based on route of administration, the market is segmented into Intravenous, subcutaneous, oral. Based on distribution channel, the market is segmented into hospital pharmacy, retail pharmacy. Based on application, the market is segmented into Prophylaxis and treatment. Based on region, the market is segmented into North America, Asia Pacific, Europe, Latin America, and MEA.

Driver

One of the main causes of misdiagnosis, resulting in patients receiving subpar care, is a lack of knowledge regarding HAE. The majority of people with hereditary angioedema have their diagnoses for appendicitis, gastrointestinal issues, and other non-allergic angioedema errors. A sizable patient population with significant medical demands has been created due to a significant number of people having their ailments wrongly diagnosed. This is likely a major market-increasing component.

Restraint

Hereditary angioedema therapy market expansion has been hampered by a misdiagnosis of the condition as common allergies, appendicitis, and irritable bowel syndrome, which has led to the suspension of treatment. One of the main reasons for misdiagnosis, which results in inadequate therapy for patients, is a lack of knowledge about HAE. Most hereditary angioedema sufferers receive incorrect diagnoses for appendicitis, gastrointestinal conditions, and other types of non-allergic angioedema. Many people have received the wrong diagnosis for the disease.

Market Trends

A factor that is fueling the market's expansion is the increase in activities aimed at raising public awareness. HAEday, which is observed annually on May 16th, is supported by HAE International (HAEi), an international patient group for people with hereditary angioedema, as well as other patient organizations from across the world. The initiative's goals include expediting diagnosis and giving patients the best possible care and treatment.

Table of Contents

Executive Summary

Market overview

• Exhibit: Executive Summary - Chart on Market Overview
• Exhibit: Executive Summary - Data Table on Market Overview
• Exhibit: Executive Summary - Chart on Global hereditary angioedema treatment market Characteristics
• Exhibit: Executive Summary - Chart on Market by Geography
• Exhibit: Executive Summary - Chart on Market Segmentation
• Exhibit: Executive Summary - Chart on Incremental Growth
• Exhibit: Executive Summary - Data Table on Incremental Growth
• Exhibit: Executive Summary - Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• SWOT Analysis

KEY MARKET INSIGHTS

• Technology Analysis
  • (Exhibit: Data Table: Name of technology and details)
• Pricing Analysis
  • (Exhibit: Data Table: Name of technology and pricing details)
• Supply Chain Analysis
  • (Exhibit: Detailed Supply Chain Presentation)
• Value Chain Analysis
  • (Exhibit: Detailed Value Chain Presentation)
• Ecosystem Of the Market
  • Exhibit: Parent Market Ecosystem Market Analysis
  • Exhibit: Market Characteristics of Parent Market
• IP Analysis
  • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
• Trade Analysis
  • (Exhibit: Data Table: Import and Export data details)
• Startup Analysis
  • (Exhibit: Data Table: Emerging startups details)
• Raw Material Analysis
  • (Exhibit: Data Table: Mapping of key raw materials)
• Innovation Matrix
  • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
• Pipeline product Analysis
  • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
• Macroeconomic Indicators

COVID IMPACT

• Introduction
• Impact On Economy-scenario Assessment
  • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
• Revised Market Size
  • Exhibit: Data Table on Global hereditary angioedema treatment market size and forecast 2022-2028 ($ million)
• Impact Of COVID On Key Segments
  • Exhibit: Data Table on Segment Market size and forecast 2022-2028 ($ million)
• COVID Strategies By Company
  • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

• Market Dynamics
  • Exhibit: Impact analysis of DROC, 2021
• Drivers
• Opportunities
• Restraints
• Challenges
• Regulatory Landscape
  • Exhibit: Data Table on regulation from different region
• SWOT Analysis
• Porters Analysis
  • Competitive rivalry
• Exhibit: Competitive rivalry Impact of key factors, 2021
  • Threat of substitute products
• Exhibit: Threat of Substitute Products Impact of key factors, 2021
  • Bargaining power of buyers
• Exhibit: buyers bargaining power Impact of key factors, 2021
  • Threat of new entrants
• Exhibit: Threat of new entrants Impact of key factors, 2021
  • Bargaining power of suppliers
• Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
• Skyquest special insights on future disruptions
  • Political Impact
  • Economic impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact
• Global hereditary angioedema treatment market by Drug class
• Market segments
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Data table on Market share 2022-2028 (%)
• C1-esterase inhibitor
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Brandykinin B2 receptor antagonist
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Kallikrein inhibitor
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• others
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Global hereditary angioedema treatment market by Treatment
• Market segments
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Data table on Market share 2022-2028 (%)
• Prophylaxis
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• On-demand
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Global hereditary angioedema treatment market by Route of administration
• Market segments
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Data table on Market share 2022-2028 (%)
• Intravenous
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Subcutaneous
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Oral
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Global hereditary angioedema treatment market by Distribution channel
• Market segments
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Data table on Market share 2022-2028 (%)
• Hospital pharmacy
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Retail Pharmacy
  • Market Estimates & Forecast, 2021-2028
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)

Market Size by Region

• Chart on Market share by geography 2022-2028 (%)
• Data Table on Market share by geography 2022-2028(%)
• North America
  • Chart on Market share by country 2022-2028 (%)
  • Data Table on Market share by country 2022-2028(%)
  • USA
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Canada
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Europe
  • Chart on Market share by country 2022-2028 (%)
  • Data Table on Market share by country 2022-2028(%)
  • Germany
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Spain
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • France
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • UK
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Rest of Europe
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Asia Pacific
  • Chart on Market share by country 2022-2028 (%)
  • Data Table on Market share by country 2022-2028(%)
  • China
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • India
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Japan
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • South Korea
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Rest of Asia Pacific
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Latin America
  • Chart on Market share by country 2022-2028 (%)
  • Data Table on Market share by country 2022-2028(%)
  • Brazil
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Rest of South America
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
• Middle East & Africa (MEA)
  • Chart on Market share by country 2022-2028 (%)
  • Data Table on Market share by country 2022-2028(%)
  • GCC Countries
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • South Africa
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)
  • Rest of MEA
• Exhibit: Chart on Market share 2022-2028 (%)
• Exhibit: Market size and forecast 2022-2028 ($ million)

KEY COMPANY PROFILES

• Competitive Landscape
  • Total number of companies covered
• Exhibit: companies covered in the report, 2021
  • Top companies market positioning
• Exhibit: company positioning matrix, 2021
  • Top companies market Share
• Exhibit: Pie chart analysis on company market share, 2021(%)
• Takeda Pharmaceutical Company Limited (Japan)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• CSL Limited (Australia)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Biocryst Pharmaceuticals (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Pharming Group N.V. (Netherlands)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Ionis Pharmaceuticals (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Novartis AG (Switzerland)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Centogene AG (Germany)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Sanofi (France)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• KalVista Pharmaceuticals (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Pfizer Inc. (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• GlaxoSmithKline plc. (U.K.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• AstraZeneca (U.K)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Medtronic (Ireland)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Eli Lilly (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• F. Hoffmann-La Roche Ltd (Switzerland)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Amgen Inc. (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Johnson & Johnson Services (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• AbbVie Inc. (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Incyte Corporation (U.S.)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments
• Bayer AG (Germany)
  • Exhibit Company Overview
  • Exhibit Business Segment Overview
  • Exhibit Financial Updates
  • Exhibit Key Developments